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In the nontransplantation field, comorbidities have
been reported to affect chemotherapy dosing, treat-
ment toxicity, survival, and quality of life of patients
with cancer. The use of comorbidity indices has facil-
itated the incorporation of comorbidities in decision
making for treatment and clinical trial design. Despite
the extensive investigations on the roles of combined
comorbidities in the field of solid malignancy, less
work has been done in hematologic malignancies [1].
With the advent of minimally toxic conditioning regi-
mens, the hematopoietic cell transplantation (HCT)
choices have been expanded to include older patients
and those with comorbidities such as HIV infection.
Therefore, it became critical to begin learning about
the impacts of multiple comorbidities on outcomes
after allogeneic HCT.The Use of a non-HCT-Specific Comorbidity
Index (CI) among HCT Recipients
The interactions between index disease and differ-
ent comorbidities have varied, based on type and de-
grees of organ involvement. Also, comorbidities have
been so diverse that systematic accounts of every pos-
sible diagnosis and degree of severity would create an
unmanageable amount of information, especially
when these data have been gathered for clinical studies
or prognostic purposes. As a result, several indices have
been introduced as a way to rate the impacts of differ-
ent comorbidities on the index disease. The Charlson
Comorbidity Index (CCI) [2] has been the most widely
used comorbidity index in predicting mortality risks in
various solid malignancies (reviewed in [3]). The CCI
was recently applied to the settings of myeloablativeClinical Research Division, Fred Hutchinson Cancer Re-
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with hematologic malignancies and successfully pre-
dicted the risks of 1-year nonrelapse mortality
(NRM) in patients given HCT from unrelated [4], or
related donors (URD, RD) [5]. Kaplan-Maier curves
showed linear worsening of survival with increasing
CCI scores, whereby better outcomes were observed
among nonmyeloablative compared to myeloablative
patients with similar CCI scores (Figure 1) [4].Developing the New HCT-Specific CI (HCT-CI)
The CCI provided an assessment of comorbidities
that were found to be important in predicting HCT
outcomes. However, the CCI had 2 major limitations
among HCT recipients. First, some of the comorbid-
ities described by Charlson were rarely encountered
either because of existing exclusion criteria, for exam-
ple, for hepatic comorbidities, or lack of inclusion of
precise laboratory data, for example, for pulmonary
comorbidities. Second, the CCI did not capture
some comorbidities that were frequently seen among
transplanted patients, such as recent infections and
psychiatric problems. As a result, the CCI identified
comorbidities in only 35% of patients, and this per-
centage was even lower in recipients of myeloablative
HCT (12%) [4].
To address these limitations, the CCI was modi-
fied in a way that better detected comorbidities among
HCT recipients [6]. First, the definitions of several co-
morbidities were remodeled by adding laboratory pa-
rameters to the clinical definitions of comorbidities.
Second, all comorbidities encountered in transplanted
patients were included in the risk assessment analysis,
including 8 new comorbidities. The study included
1055 patients with different hematological diseases
who were given allogeneic HCT after nonmyeloabla-
tive (n5 249) ormyeloablative (n5 761) conditioning.
Two-thirds of the patients were randomly assigned to
a training set and one-third to a validation set. Integer
weights of comorbidities were calculated based on ad-
justed hazard ratios (HRs) from Cox proportional haz-
ard models of 2-year NRM. The new HCT-CI
included 17 comorbidities acquiring scores from 1 to
3. Comparing the new HCT-CI to the CCI, 9 comor-
bidities increased in relative importance. Of the 8 new149
Figure 1. Comparing nonmyeloablative andmyeloablative patients for (A) NRM and (B) survival as stratified by CCI scores. From Sorror et al. [4] Blood.
2004;104:961-968.
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plant infections, and psychiatric disturbances, whereas
signed weights in the HCT-CI, whereas the remaining
5 acquired a score of 0.
In the training set, HCT-CI scores of 0, 1, 2, 3, and
$ 4 predicted 2-year NRM of 9%, 14%, 27%, 41%,
and 43%, respectively. In the validation set, HCT-
CI scores showed higher sensitivity than the CCI
scores in capturing comorbidities. HCT-CI scores of
1-2 and $3 were found in 34% and 28% of patients,
whereas only 10% and 3% of patients had CCI scores
of 1 and$2, respectively. Most importantly, HCT-CI
scores of 0, 1-2 and $3 showed linear predictions of
NRM (14%, 21%, and 41%) and survival (71%,Figure 2. Prediction of NRM and survival by HCT-CI scores among patients60%, and 34%), respectively (Figure 2). In addition,
the HCT-CI scores showed higher discriminative
power than the CCI scores both for NRM (c statistic
of 0.692 versus 0.546, P\ .001) and survival (c statistic
of 0.661 versus 0.561, P\ .001).Correlations between Comorbidities and
Intensity of Conditioning Regimens
The advent of the HCT-CI allowed in-depth
investigation of the role of multiple comorbidities in
determining how patients with myelogenous or lym-
phogenous malignancies tolerated either nonmyeloa-
blative or myeloablative conditioning.of the validation set. From Sorror et al. [6] Blood. 2005;106:2912-2919.
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(AML) or myelodysplasitic Syndrome (MDS)
Retrospective studies have shown similar survival
among overall patients with AML andMDS after non-
myeloablative compared to myeloablative condition-
ing. Refined risk-stratification is required to design
prospective trials. We analyzed outcomes among
patients with AML (n5 391) or MDS (n5 186) given
either nonmyeloablative (n 5 125) or myeloablative
conditioning (n 5 452). Multivariate analyses of risk
factors among all patients showed that high HCT-CI
scores and high disease risk were the most significant
factors predicting NRM (P \ .0001 and P 5 .004),
overall survival (OS) (P\ .0001 and P\ .0001), and
relapse-free survival (RFS) (P \ .0001 and P \
.0001), respectively. Therefore, we stratified all pa-
tients into 4 risk groups incorporating the impacts of
both comorbidities and disease-risk (Table 1). Overall,
nonmyeloablative patients tended to have lower
incidences of NRM and higher incidences of relapse
compared to myeloablative patients resulting in com-
parable rates of OS and RFS (Table 1). Patients with
low comorbidity scores could be candidates for
prospective randomized trials comparing nonmyeloa-
blative and myeloablative conditioning regardless of
disease status. Novel antitumor agents combined with
nonmyeloablativeHCT should be explored among pa-
tients with high comorbidity scores and advanced dis-
ease. The current results demonstrated the importance
of incorporating comorbidities in the assessment of
HCT outcomes and the design of prospective trials
for patients with AML/MDS [7].Patients with lymphoma or chronic lymphocytic
leukemia (CLL)
We compared outcomes among patients with lym-
phoma or CLL given either nonmyeloablative (n 5
152) or myeloablative (n5 68) conditioning. In multi-
variate analyses for risk factors, conditioning intensity
and HCT-CI scores were the major predictive factors
for NRM and OS. Patients without comorbidities,Table 1. Two-Year NRM, Relapse, OS, and RFS Incidences amon
Stratified into 4 Risk Groups Based on HCT-CI Scores and Disease S
Risk Groups Patients
Group I (HCT-CI scores 0-2 and low-risk
diseases)
Myeloablative (n 5 138)
Nonmyeloablative (n 5 2
Group II (HCT-CI scores 0-2 and intermediate
and high-risk diseases)
Myeloablative (n 5 176)
Nonmyeloablative (n 5 3
Group III (HCT-CI scores $ 3 and low-risk
diseases)
Myeloablative (n 5 52)
Nonmyeloablative (n 5 1
Group IV (HCT-CI scores $3 and intermediate
and high-risk diseases)
Myeloablative (n 5 86)
Nonmyeloablative (n 5 4
HCT-CI indicates hematopoietic cell transplant-comorbidity index; NRM, norboth in the nonmyeloablative and myeloablative co-
horts, had comparable NRM (P 5 .74), relapse (P 5
.43), OS (P 5 .75), and RFS (P 5 .40). No significant
differences were observed (P 5 .91, P 5 .27, P 5 .89,
andP5 .40, respectively) after adjustment for pretrans-
plant variables. Patients with comorbidities experi-
enced lower NRM (P 5 .009) but similar relapse (P5
.22), resulting in better OS (P5 .04) after nonmyeloa-
blative conditioning.NRMandOSdifferences became
more significant (P\ .0001 and .0007, respectively) af-
ter adjustment for other variables (Figure 3). Further,
nonmyeloablative patients with comorbidities had
favorable adjusted RFS (P 5 .01). Patients without
comorbidities could be enrolled in prospective ran-
domized studies comparing different conditioning in-
tensities. Younger patients with comorbidities might
benefit from reduced-intensity conditioning (RIC)
The use of the HCT-CI allowed for more appropriate
assignment of patients to different intensity condition-
ing regimens [8].The Use of the HCT-CI to Compare Outcomes
at 2 Different Institutions
We compared the performance of the HCT-CI to
2 other indices and then tested its capacity to predict
outcomes among 2 cohorts of patients diagnosed
with a single disease entity, AML in first complete re-
mission (CR1), transplanted at either FredHutchinson
Cancer Research Center (FHCRC) or MD Anderson
Cancer (MDACC). Comorbidity data for the FHCRC
and MDACC patients were extracted by 2 indepen-
dent investigators. FHCRC patients less frequently
had unfavorable cytogenetics (15% versus 36%) and
HCT-CI of $3 (21% versus 58%) compared to
MDACC patients. We found that the HCT-CI had
higher sensitivity and outcome predictability com-
pared to the other indices among both cohorts.
HCT-CI scores of 0, 1-2, and $3 predicted compara-
ble NRM (7% versus 7%, 19% versus 21%, and 37%
versus 27%) among FHCRC versusMDACCpatients,
respectively. In multivariate models, HCT-CI scoresg Nonmyeloablative Compared to Myeloablative Patients as
tatus
NRM (%) Relapse (%) OS (%) RFS (%)
11 14 78 75
8) 4 33 70 63
24 34 51 43
4) 3 42 57 56
32 27 45 41
9) 27 37 41 36
46 34 24 20
4) 29 49 29 23
relapse mortality; OS, overall survival; RFS, relapse-free survival.
Figure 3. Cumulative incidence estimates of NRM and Kaplan Meier survival estimates among nonmyeloablative compared to myeloablative patients
with lymphoma or CLL and HCT-CI score $1. From Sorror et al. [8] Blood. 2008;111:446-452.
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NRM and survival among each cohort. The 2-year
survival rates among FHCRC and MDACC patients
were 71% versus 56%, respectively. After adjustment
for risk factors, including HCT-CI scores, no differ-
ence in survival was detected (HR: 0.98, P 5 .94).
The HCT-CI was shown to be an informative tool
to compare trial results at different institutions. [9]The Independent Roles of the HCT-CI and the
Karnofsky Performance Status (KPS)
Performance status scales, such as KPS, are fre-
quently used as estimates of overall patient health at
HCT. The extent to which this scale reflects on the
burden of comorbidities in transplanted patients is
not well known. Therefore, we evaluated predictive
factors for outcomes of 339 patients with hematologic
diseases given nonmyeloablative conditioning and al-
logeneic HCT at 5 different academic institutions.
Weak Spearman rank correlations were noted between
HCT-CI and KPS. In multivariate models, the HCT-
CI had significantly greater independent predictive
power for toxicities (P 5 .004), NRM (P 5 .0002),Table 2. Multivariate Analyses of Risk Factors
NRM
HR P
HCT-CI scores 0 1.0 .50
1-2 1.55
$ 3 6.63 .0009
Age, years <60 1.0 .73
.62 $ 60 0.84
LDH Normal 1.0 .27
Abnormal 1.56
Chemosensitivity Yes 1.0 .71
No 1.2
LDH indicates lactate dehydrogenase; NRM, nonrelapse mortality; RFS, relapse
HR, hazard ratio.and overall mortality (P 5 .0002) compared to the
KPS (P 5 .05, 0.13, and 0.05, respectively). Patients
with HCT-CI scores of 0-2 or $3 were further strati-
fied based onKPS percentages of.80% versus# 80%
into 4 risk groups with 2-year survivals of 68%, 58%,
41%, and 32%, respectively. In conclusion, HCT-CI
and KPS should be assessed simultaneously before
HCT. The use of both tools combined likely refines
risk-stratification for HCT outcomes [10].Role of the HCT-CI in the Autologous HCT
Setting
We asked whether the HCT-CI could provide
prognostic information among patients (n 5 273)
with lymphoma given autologous HCT. HCT-CI co-
morbidities (score .0) were found among 65% of pa-
tients, of whom 16% had score 1, 19% score 2, 26%
scores 3-4, and 4% scores $5. In multivariate models
(Table 2), HCT-CI scores independently predicted
NRM and, together with LDH and chemosensitive
disease, predicted OS and RFS. Patients with HCT-
CI scores of 0 versus 1-2 versus $3 had 2-year NRM
of 3%, 8%, and 19%, and OS of 80%, 78%, and 52%,Mortality RFS
HR P HR P
1.0 .80 1.0 .62
1.8 1.13
2.89 <.0001 1.13 0.001
1.0 .31 1.0 .16
1.28 1.35
1.0 .001 1.0 .01
2.01 1.58
1.0 .02 1.0 .005
1.61 1.7
-free survival; HCT-CI, hematopoietic cell transplant-comorbicity index;
Biol Blood Marrow Transplant 15:149-153, 2009 153Vulnerable Transplant Patientsrespectively. In conclusion, patients with HCT-CI
scores of 0 and 1-2 tolerated high-dose conditioning
equally well, whereas scores $3 were associated with
increasing mortality [11].
CLINICAL SIGNIFICANCE AND FUTURE
AIMS
In summary, the advent of the HCT-CI allowed
for more accurate evaluation of the burden of comor-
bidities at the time of HCT. Further, the HCT-CI
proved to be a sensitive tool in predicting outcomes
among patients diagnosed with lymphogenous or
myelogenous malignancies and given allogeneic or
autologousHCT. It provides additional prognostic in-
formation to performance status scales and could be
used to correct for comparisons or trial outcomes. In
the future, it would be important to (1) validate the
predictive capacity of the HCT-CI among patients
transplanted at multiple institutions and reported to
transplant registry database, (2) assess reliability
among different evaluators (interrater reliability) and
at different time intervals (test-retest reliability), (3) in-
vestigate the interaction between comorbidity scores
and other important risk factors, namely, age to further
enhance the predictive capacity of the HCT-CI, (4)
develop new methods to standardize comorbidity
data collection and shorten time and effort required
for assessment to ensure wide spread inclusion of the
HCT-CI in future clinical trials, and (5) study in depth
the biological impacts of comorbidities on causes of
death and post-HCT complications including graft-
versus-host disease (GVHD).
Achievement of these objectives could result in at
least 3 future scientific goals. First, the development
of strong prognostic tools would allow determining
which patients could tolerate high-dose myeloablative
HCT,whichwould benefit from the less toxic nonmye-
loablative HCT, and which would not benefit at all
from allogeneic HCT. Further, results would provide
scientific basis for future design of clinical trials explor-
ing novel conditioning or GVHD prophylaxis regi-
mens for particular groups of patients. Finally,
refining estimates of outcomes of newly investigated
treatment approaches would allow more rational com-
parisons of trial results from different institutions.ACKNOWLEDGMENTS
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